Brexit And International Reference Pricing To Cost Companies Billions Of Dollars
Executive Summary
Companies could lose hundreds of millions of dollars thanks to the impact of Brexit on international reference pricing. Brexit has other market access implications too, for example on the ebb and flow of parallel trade.
You may also be interested in...
EMA’s Post-Brexit Home ‘Could Be Decided This Year’
The leader of Denmark’s bid to host the European Medicines Agency after the UK leaves the EU says that a rapid decision-making process on the agency’s new location is needed in order to avoid entanglements with the wider Brexit negotiations, and that a decision could be taken sometime in the second half of this year.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.